<DOC>
	<DOCNO>NCT01673490</DOCNO>
	<brief_summary>Open-label , 6 month-treatment IP subject . - Sample size : A total 90 subject enrol among least 57 complete 6-month treatment period evaluable analysis . -Primary objective : To assess safety 0.5 mg dutasteride/0.4 mg tamsulosin combination therapy six month BPH patient monitor category , frequency severity adverse event encounter treatment period . -Secondary objective : To assess efficacy 0.5 mg dutasteride/0.4 mg tamsulosin combination therapy regard symptom improvement BPH patient monitor analyze change IPSS Qmax 6 month treatment .</brief_summary>
	<brief_title>Safety Efficacy 0.5mg Dutasteride 0.4mg Tamsulosin Combination Once Daily Six Months Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>Visit 0 Screening Visit ( M0 ) - D0 + 2 ) : Following task perform : ICF collection , subject code assignment , physical examination ( vital sign , demographic data , medical history ) ; check inclusion exclusion criterion : prostate symptom score accord IPSS , laboratory test ( hematology , blood chemistry , electrolytes , total PSA level , free-to-total PSA ratio , Qmax , urinalysis , transrectal prostate ultrasonography ( TRUS ) , 12-lead electrocardiography ( ECG ) , score Sexual Function Questionnaire ( SFQ ) , concomitant medication assessment , IP dispense . • Visit 1 ( Month 1 ( M1 ) - D30 ± 3 ) : Following item record : treatment compliance , vital sign , blood chemistry , ECG , adverse event ( AEs ) , concomitant medication ; dispense new IP dose collect dispense IP last visit . • Visit 2 ( Month 2 ( M2 ) - D60 ± 3 ) : Following item record : treatment compliance , AEs , concomitant medication ; dispense new IP dose collect dispense IP last visit . • Visit 3 ( Month 3 ( M3 ) - D90 ± 3 ) : Following item record : vital sign , laboratory test ( hematology , blood chemistry , electrolytes , Qmax , urinalysis , 12-lead ECG , total PSA level ) , concomitant medication , SFQ score , AE assessment , collect dispense IP last visit dispense new IP dos . • Visit 4 ( Month 4.5 ( M4 ) - D135 ± 3 ) : Following item record : treatment compliance , vital sign , AEs , concomitant medication ; dispense new IP dose collect dispense IP last visit . Visit 5 ( Month 6 ( M6 ) - D180 ± 3 ) : Following item record : treatment compliance , vital sign , prostate symptom score accord IPSS , laboratory test ( hematology , blood chemistry , electrolytes , Qmax , urinalysis , 12-lead ECG , total PSA level , free-to-total PSA ratio , TRUS ; concomitant medication , SFQ score , AE assessment , collect previous dispense IPs . Follow-up Phone Call ( Month 7 ( M7 ) - D210 ± 3 ) : To record possible AE may occur discontinuation study treatment .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Male , age ≥ 50 year . Clinical diagnosis benign prostate hypertrophy ( BPH ) . International Prostate Symptom Score ( IPSS ) ≥ 12 Prostate volume ≥30 ml ( transrectal ultrasonography ) . Total serum prostate specific antigen ( PSA ) ≥1.5 ng/mL ≤10 ng/mL . Freetototal PSA ratio &gt; 20 % Maximum flow rate ( Qmax ) &gt; 5 mL/sec ≤15 mL/sec postvoid residual volume &lt; 150 mL Willing able give write informed consent comply study procedure throughout study Able swallow retain oral medication Able express personal thought feel Ability read comprehend information Sexual Function Inventory History evidence prostate cancer ( e.g . positive biopsy ultrasound , suspicious digital rectal examination ) . Previous prostatic surgery ( TURP , balloon dilatation , thermotherapy stent replacement ) invasive procedure treat BPH . History flexible/rigid cystoscopy instrumentation urethra within past 7 day History acute urine retention ( AUR ) within past 3 month . Any cause BPH result urinary symptom change flow rate ( e.g . neurogenic bladder , bladder neck contracture , urethral stricture , bladder malignancy , acute chronic prostatitis , acute chronic urinary tract infection ) . History breast cancer clinical find suggestive malignancy . Use 5alphareductase inhibitor ( e.g . Proscar® , Propecia® ) , drug antiandrogenic property ( e.g . spironolactone , flutamide , bicalutamide , cimetidine , ketoconazole , progestational agent ) , drug induce gynecomastia drug affect prostate volume , within past 6 month throughout study ( study medication ) . Do use dutasteride within past 12 month . Do use metronidazole long time . Concurrent use anabolic steroid ( eg . Durabolin® ) . Use phytotherapy ( eg : Tadenan® , Permixon® , etc ) BPH within 2 week screen visit and/or predict need phytotherapy study . Use alphaadrenoreceptor blocker ( i.e . indoramin , prazosin , terazosin , tamsulosin , alfuzosin doxazosin ) within 2 week screen visit and/or predict need alpha blocker tamsulosin study . Use alphaadrenoreceptor agonist ( e.g . pseudoephedrine , phenylephrine , ephedrine ) anticholinergic ( e.g . oxybutynin , propantheline ) cholinergics ( e.g . bethanecol chloride ) within 48 hour prior uroflowmetry assessment . Hypersensitivity alpha/betaadrenoreceptor blocker 5alphareductase inhibitor , chemicallyrelated drug . Concurrent use drug know thought interaction tamsulosin dutasteride . History hepatic impairment abnormal liver function test screen ( defined ALT , AST , and/or alkaline phosphatase &gt; 2 time upper limit normal , total bilirubin &gt; 1.5 time upper limit normal ) . History renal insufficiency , serum creatinine &gt; 1.5 time upper limit normal screening . History malignancy basal cell carcinoma squamous cell carcinoma skin within past 5 year . Subjects prior malignancy evidence disease least 5 year prior screen eligible . Any unstable , serious coexist medical condition ( ) include , limited , myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within past 6 month ; medically uncontrollable diabetes peptic ulcer disease History postural hypotension , dizziness , vertigo sign symptom orthostasis , judgment investigator , could exacerbate tamsulosin History unsuccessful treatment tamsulosin 'first dose ' hypotensive episode initiation alpha1adrenoreceptor antagonist therapy . History unsuccessful treatment finasteride dutasteride . Willing child treatment period within 6 month thereafter Having female partner pregnant woman childbearing age refuse use condom sexual protection Willing donate blood treatment period within 6 month thereafter . History current evidence drug alcohol abuse within past 12 month . History illness might confound result study pose additional risk patient . Participation investigational market drug trial within 30 day precede screen visit and/or study treatment</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>dutasteride tamsulosin</keyword>
</DOC>